Open AccessRavulizumab (Ultomiris)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.319
Subject(s) - reimbursement , paroxysmal nocturnal hemoglobinuria , medicine , family medicine , business , political science , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses ravulizumab (Ultomiris), 10 mg/mL concentrate for solution for infusion.
Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.